WallStSmart

Novo Nordisk A/S (NVO)vsOklo Inc. (OKLO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

NVO leads profitability with a 33.1% profit margin vs 0.0%. NVO earns a higher WallStSmart Score of 55/100 (C).

NVO

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 10.0Value: 4.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.08

OKLO

Avoid

28

out of 100

Grade: F

Growth: 5.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVOSignificantly Overvalued (-59.4%)

Margin of Safety

-59.4%

Fair Value

$24.21

Current Price

$36.33

$12.12 premium

UndervaluedFair: $24.21Overvalued

Intrinsic value data unavailable for OKLO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVO5 strengths · Avg: 9.8/10
P/E RatioValuation
10.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
60.7%10/10

Every $100 of equity generates 61 in profit

Profit MarginProfitability
33.1%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
44.5%10/10

Strong operational efficiency at 44.5%

Market CapQuality
$165.02B9/10

Large-cap with strong market position

OKLO1 strengths · Avg: 8.0/10
EPS GrowthGrowth
29.7%8/10

Earnings expanding 29.7% YoY

Areas to Watch

NVO4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Revenue GrowthGrowth
-7.6%2/10

Revenue declined 7.6%

EPS GrowthGrowth
-4.7%2/10

Earnings declined 4.7%

OKLO4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.

Bull Case : OKLO

The strongest argument for OKLO centers on EPS Growth.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : OKLO

The primary concerns for OKLO are Revenue Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

NVO profiles as a declining stock while OKLO is a value play — different risk/reward profiles.

OKLO carries more volatility with a beta of 0.82 — expect wider price swings.

OKLO is growing revenue faster at 0.0% — sustainability is the question.

OKLO generates stronger free cash flow (-60M), providing more financial flexibility.

Bottom Line

NVO scores higher overall (55/100 vs 28/100), backed by strong 33.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Oklo Inc.

UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA

Oklo Inc. designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States. The company is headquartered in Santa Clara, California.

Want to dig deeper into these stocks?